Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
4
×
detroit blog main
detroit top stories
gilead sciences
4
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
4
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
alzheimer's disease
biogen
boston top stories
deals
europe blog main
europe top stories
aducanumab
astrazeneca
cancer immunotherapy
What
bio
roundup
acquisitions
ceo
covid
daniel
drug
gilead
ipo
medicines
new
o’day
sciences
activity
announced
approval
approvals
biggest
biogen
biogen’s
biopharmaceutical
build
buy
clamped
collabs
companies
company’s
convo
deal
debut
delays
developing
dyne’s
earlier
economic
failures
fast
fda
gilead’s
help
Language
unset
Current search:
startups
×
" gilead sciences "
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More